CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Bausch & Lomb

BLCO
$5.30B
Mid Cap
NASDAQOphthalmic GoodsMedical instruments🇺🇸North AmericaVAUGHAN12.9K employees

Bausch & Lomb (since 2010 stylized as Bausch + Lomb) is a Canadian eye health products company based in Vaughan, Ontario, Canada. It is one of the world's largest suppliers of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. The company was founded in Rochester, New York, in 1853 by optician John Bausch and cabinet maker turned financial backer Henry Lomb. Until its sale in 2013, Bausch + Lomb was one of the oldest continually operating companies in the United States.

Website

Drugs in Pipeline

61

Phase 3 Programs

42

Upcoming Catalysts

1

Next Catalyst

Jul 29, 2026

9d

Market Overview

Stock performance and key metrics

BLCO News
Catalyst Timeline

1 upcoming, 0 past

EarningsNext

BLCO Earnings Report

Jul 29, 2026

EPS Est: $0.16 | FQ end 2026-06 | Call: 2026-07-29 15:00:00

How BLCO's past catalysts played out

earningsMay 2024-6%earningsFeb 2024+14%earningsNov 2022-6%earningsAug 2022+5%
Drug Pipeline

Bepotastine besilate

Phase 3

Seasonal Allergic Rhinitis

Bromfenac Ophthalmic Solution

Phase 3

Pain

Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation

Phase 3

Ocular Redness

Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%

Phase 3

Allergic Conjunctivitis

T-PRED

Phase 3

Cataract

ISV-403

Phase 3

Acute Bacterial Conjunctivitis

Ecabet 2.83%

Phase 3

Dry Eye Syndromes

Fluocinolone acetonide 2.1mg

Phase 3

Noninfectious Posterior Uveitis

Sodium Fluorescein

Phase 3

Hyperemia

Naphazoline

Phase 3

Allergic Conjunctivitis

fluocinolone acetonide

Phase 3

Diabetic Macular Edema

Bepreve

Phase 3

Conjunctivitis, Allergic

Timolol

Phase 3

Open-Angle Glaucoma

Loteprednol and tobramycin

Phase 3

Conjunctivitis

Prednisolone and Tobramycin

Phase 3

Eye Infections

Azopt 1%

Phase 3

Glaucoma

Pred Forte

Phase 3

Cataract

Besifloxacin

Phase 3

Acute Bacterial Conjunctivitis

Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)

Phase 3

Allergic Conjunctivitis

BTOS-HA

Phase 3

Ocular Redness

Bepreve (bepotastine besilate ophthalmic solution) 1.5%

Phase 3

Allergic Conjunctivitis

brinzolamide 1% ophthalmic suspension

Phase 3

Glaucoma

0.5% Loteprednol Etabonate Ophthalmic Ointment

Phase 3

Ocular Inflammation

BOL-303259-X

Phase 3

Ocular Hypertension

Bromfenac

Phase 3

Postoperative Complications

Loteprednol etabonate

Phase 3

Cataract

Besivance

Phase 3

Bacterial Conjunctivitis

Loteprednol Etabonate Gel (TID)

Phase 3

Inflammation

EM-100

Phase 3

Allergic Conjunctivitis

Brimonidine Tartrate

Phase 3

Hyperemia

Latanoprostene bunod

Phase 3

Glaucoma

Loteprednol Etabonate Gel (BID)

Phase 3

Inflammation

Ketotifen/naphazoline

Phase 3

Allergic Conjunctivitis

Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution

Phase 3

Seasonal Allergic Conjunctivitis

Loteprednol Etabonate Ophthalmic Gel dosed TID

Phase 3

Cataract

Bromfenac Ophthalmic Solution A

Phase 3

Dry Eye Syndrome

Loteprednol etabonate 0.2%

Phase 3

Seasonal Allergic Conjunctivitis

Vitrase

Phase 3

Pain

KetoNaph

Phase 3

Allergic Conjunctivitis

fluocinolone acetonide intravitreal implant

Phase 3

Non-infectious Uveitis

Mapracorat

Phase 3

Cataract

NOV03

Phase 3

Dry Eye Disease (DED)

bromfenac ophthalmic solution 0.06%

Phase 2

Dry Eye Disease

Ecabet

Phase 2

Dry Eye Syndromes

Bepotastine besilate formulation

Phase 2

Seasonal Allergic Rhinitis

Bepotastine Besilate Nasal Spray 2% Twice a day

Phase 2

Seasonal Allergic Rhinitis

0.59 mg fluocinolone acetonide intravitreal implant

Phase 2

Diabetic Macular Edema

BOL-303242-X

Phase 2

Cataract

BL1107 Low dose

Phase 2

Glaucoma

PF-03187207 and Latanoprost Vehicle

Phase 2

Primary Open Angle Glaucoma

Lifitegrast/Perfluorohexyloctane Fixed Dose Combination

Phase 2

Dry Eye Disease

bepotastine besilate nasal product - low dose

Phase 2

Seasonal Allergic Rhinitis

loteprednol etabonate ophthalmic suspension, 0.5%

Phase 2

Dry Eye

0.3% BOL-303242-X ophthalmic suspension

Phase 2

Dry Eye Syndrome

Loteprednol etabonate base (QD)

Phase 2

Allergic Conjunctivitis

bepotastine besilate ophthalmic solution

Phase 2

Allergic Conjunctivitis

PF-03187207

Phase 2

Primary Open Angle Glaucoma

ecabet ophthalmic solution

Phase 2

Dry Eye Disease

WB007 0.05%

Phase 2

Glaucoma, Primary Open Angle

Lotemax

Phase 2

Keratoconjunctivitis Sicca

Latanoprost

Phase 2

Intraocular Pressure

📑
Catalyst DossierPRO
The full research note — thesis, the if-approved scenario, financials & smart money. Compiled by CeliA.
→
Catalyst Verdict

Full breakdown — the signals behind the verdict

Market-Implied Move
Regulatory Approvals

Frequently asked questions

What is in Bausch & Lomb's drug pipeline?→

CatalystAlert tracks 61 drug candidates in Bausch & Lomb's (BLCO) pipeline across Phase 3, Phase 2. Its lead program is Bepotastine besilate (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Bausch & Lomb's next FDA catalyst?→

Bausch & Lomb's (BLCO) next tracked catalyst is a Earnings expected July 29, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track BLCO biotech catalysts?→

Add BLCO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Bausch & Lomb's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply